Related Experiment Videos
Optimal regimes for local IL-2 tumour therapy
W Den Otter1, J W De Groot, M R Bernsen
1Department of Functional Morphology, Faculty of Veterinary Medicine, Utrecht, The Netherlands.
International Journal of Cancer
|May 3, 1996
Summary
Optimizing regional interleukin-2 (IL-2) therapy is crucial for cancer treatment. Studies in murine models show specific dose, schedule, and injection site regimens significantly improve anti-tumour responses and cure rates.
Area of Science:
- Immunotherapy
- Cancer Research
- Pharmacology
Background:
- Regional interleukin-2 (IL-2) therapy is a promising approach for cancer treatment.
- Optimal administration parameters for regional IL-2 therapy require further investigation.
Purpose of the Study:
- To determine the optimal dose, schedule, and site of injection for regional IL-2 therapy.
- To evaluate the efficacy of optimized regional IL-2 therapy in murine tumor models.
Main Methods:
- Studies were conducted in two distinct murine tumor models.
- Interleukin-2 (IL-2) was administered regionally with variations in dose, frequency, and injection site.
- Anti-tumor responses and cure rates were assessed.
Main Results:
- Dose, schedule, and site of injection were all critical factors for effective regional IL-2 therapy.
- Optimal anti-tumor responses were achieved with 5 to 10 regional IL-2 administrations daily or every other day, at doses of 7,000 to 33,000 IU/day.
- These optimized regimens resulted in cure rates exceeding 40% in mice with disseminated tumors.
Conclusions:
- The identified optimal parameters for regional IL-2 therapy demonstrate significant anti-tumor efficacy in murine models.
- The findings suggest that these optimized IL-2 administration strategies may have broader applicability beyond the specific tumor models studied.